IL292658A - Immune modulation with tlr9 agonists for cancer treatment - Google Patents
Immune modulation with tlr9 agonists for cancer treatmentInfo
- Publication number
- IL292658A IL292658A IL292658A IL29265822A IL292658A IL 292658 A IL292658 A IL 292658A IL 292658 A IL292658 A IL 292658A IL 29265822 A IL29265822 A IL 29265822A IL 292658 A IL292658 A IL 292658A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- combination
- use according
- imo
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394845P | 2016-09-15 | 2016-09-15 | |
| US201762486738P | 2017-04-18 | 2017-04-18 | |
| PCT/US2017/051742 WO2018053242A1 (en) | 2016-09-15 | 2017-09-15 | Immune modulation with tlr9 agonists for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292658A true IL292658A (en) | 2022-07-01 |
Family
ID=61620152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292658A IL292658A (en) | 2016-09-15 | 2017-09-15 | Immune modulation with tlr9 agonists for cancer treatment |
| IL265370A IL265370B (en) | 2016-09-15 | 2019-03-14 | Immune modulation with tlr9 agonists for cancer therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265370A IL265370B (en) | 2016-09-15 | 2019-03-14 | Immune modulation with tlr9 agonists for cancer therapy |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10463686B2 (https=) |
| EP (1) | EP3512499A4 (https=) |
| JP (2) | JP7200093B2 (https=) |
| KR (1) | KR20190096936A (https=) |
| CN (1) | CN110114057A (https=) |
| AU (1) | AU2017325981A1 (https=) |
| CA (1) | CA3036978A1 (https=) |
| IL (2) | IL292658A (https=) |
| MX (1) | MX2019002925A (https=) |
| WO (1) | WO2018053242A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105579582A (zh) | 2013-07-25 | 2016-05-11 | 埃克西奎雷股份有限公司 | 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体 |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| JP7200093B2 (ja) | 2016-09-15 | 2023-01-06 | アイデラ・ファーマシューティカルズ，インコーポレーテッド | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| JP2022512745A (ja) * | 2018-10-18 | 2022-02-07 | アイデラ・ファーマシューティカルズ，インコーポレーテッド | がんを処置するためのｔｌｒ９調節因子 |
| KR20210087454A (ko) * | 2018-11-01 | 2021-07-12 | 파론 파머수티컬스 오와이 | 대체 활성화되는 대식세포 상의 clever-1 발현을 억제하는데 사용하기 위한 tlr9 작용제 |
| BR112021012536A2 (pt) | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
| US20230072809A1 (en) * | 2020-03-09 | 2023-03-09 | Dynavax Technologies Corporation | Active booster immunization against tetanus, diphtheria and pertussis |
| DE112021004970T5 (de) * | 2020-09-22 | 2023-07-06 | Trisalus Life Sciences, Inc. | Krebstherapie unter verwendung von toll-like-rezeptor-agonisten |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1200580T3 (da) | 1999-08-13 | 2005-04-11 | Hybridon Inc | Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation |
| US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| JP4188687B2 (ja) | 2000-12-27 | 2008-11-26 | ダイナバックス テクノロジーズ コーポレイション | 免疫変調ポリヌクレオチド及びその使用法 |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| PT1992635E (pt) * | 2002-12-23 | 2012-03-20 | Dynavax Tech Corp | Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| MXPA05013658A (es) | 2003-06-11 | 2006-03-02 | Hybridon Inc | Oligonucleotidos inmunomoduladores estabilizados. |
| CN100482673C (zh) | 2003-07-15 | 2009-04-29 | 艾德拉药物股份有限公司 | 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用 |
| MXPA06000619A (es) | 2003-07-15 | 2006-04-11 | Hybridon Inc | Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion. |
| US20060014713A1 (en) | 2004-06-15 | 2006-01-19 | Hybridon, Inc. | Immunostimulatory oligonucleotide multimers |
| US7427405B2 (en) | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| JP2009500412A (ja) | 2005-07-07 | 2009-01-08 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療 |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| US7786089B2 (en) | 2005-12-20 | 2010-08-31 | Idera Pharmaceuticals, Inc. | Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments |
| US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
| MX2009006230A (es) | 2006-12-12 | 2009-06-22 | Idera Pharmaceuticals Inc | Agonistas sinteticos de receptores de tipo toll 9. |
| KR20100053598A (ko) | 2007-08-01 | 2010-05-20 | 이데라 파마슈티칼즈, 인코포레이티드 | Ｔｌｒ９의 신규한 합성 효능제 |
| US20110293565A1 (en) | 2009-01-30 | 2011-12-01 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| EP2533779A4 (en) | 2010-02-09 | 2013-08-21 | Georgia Health Sciences University Res Inst Inc | ALPHA-METHYL-TRYPTOPHANE AS INHIBITORS OF INDOLEAMINE DIOXYGENASE |
| BR112012029066A2 (pt) | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| FR2975600B1 (fr) * | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| US9308253B2 (en) * | 2011-09-19 | 2016-04-12 | The Johns Hopkins University | Cancer immunotherapy |
| CN105163754B (zh) | 2012-09-20 | 2018-01-05 | 王荣福 | 前列腺特异性肿瘤抗原及其用途 |
| JP6508785B2 (ja) | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| WO2016030863A1 (en) * | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| JP6991857B2 (ja) * | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| ES3011733T3 (en) * | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| CN107708706A (zh) | 2015-05-29 | 2018-02-16 | 戴纳瓦克斯技术公司 | 用于治疗肺的癌症的多核苷酸Toll样受体9激动剂的肺内施用 |
| US10751412B2 (en) | 2015-05-29 | 2020-08-25 | Merck Sharp & Dohme Corp. | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
| JP7200093B2 (ja) | 2016-09-15 | 2023-01-06 | アイデラ・ファーマシューティカルズ，インコーポレーテッド | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 |
-
2017
- 2017-09-15 JP JP2019514720A patent/JP7200093B2/ja active Active
- 2017-09-15 US US15/705,631 patent/US10463686B2/en not_active Expired - Fee Related
- 2017-09-15 KR KR1020197010562A patent/KR20190096936A/ko not_active Ceased
- 2017-09-15 CA CA3036978A patent/CA3036978A1/en active Pending
- 2017-09-15 IL IL292658A patent/IL292658A/en unknown
- 2017-09-15 EP EP17851589.6A patent/EP3512499A4/en not_active Withdrawn
- 2017-09-15 AU AU2017325981A patent/AU2017325981A1/en not_active Abandoned
- 2017-09-15 CN CN201780067972.4A patent/CN110114057A/zh active Pending
- 2017-09-15 MX MX2019002925A patent/MX2019002925A/es unknown
- 2017-09-15 WO PCT/US2017/051742 patent/WO2018053242A1/en not_active Ceased
-
2019
- 2019-03-14 IL IL265370A patent/IL265370B/en unknown
- 2019-08-30 US US16/557,630 patent/US10772907B2/en not_active Expired - Fee Related
- 2019-08-30 US US16/557,597 patent/US10835550B2/en not_active Expired - Fee Related
-
2020
- 2020-09-14 US US17/020,355 patent/US20210052625A1/en not_active Abandoned
- 2020-10-21 US US17/076,677 patent/US11224611B2/en not_active Expired - Fee Related
-
2021
- 2021-10-18 JP JP2021170043A patent/JP2022009200A/ja active Pending
- 2021-12-06 US US17/543,341 patent/US20220088054A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3512499A4 (en) | 2020-08-05 |
| US20180125877A1 (en) | 2018-05-10 |
| US11224611B2 (en) | 2022-01-18 |
| US10835550B2 (en) | 2020-11-17 |
| JP2022009200A (ja) | 2022-01-14 |
| JP2019529415A (ja) | 2019-10-17 |
| KR20190096936A (ko) | 2019-08-20 |
| US10772907B2 (en) | 2020-09-15 |
| IL265370B (en) | 2022-06-01 |
| MX2019002925A (es) | 2019-09-05 |
| US20210038630A1 (en) | 2021-02-11 |
| JP7200093B2 (ja) | 2023-01-06 |
| CA3036978A1 (en) | 2018-03-22 |
| US20210052625A1 (en) | 2021-02-25 |
| AU2017325981A1 (en) | 2019-04-11 |
| WO2018053242A1 (en) | 2018-03-22 |
| US20200054663A1 (en) | 2020-02-20 |
| EP3512499A1 (en) | 2019-07-24 |
| CN110114057A (zh) | 2019-08-09 |
| US20220088054A1 (en) | 2022-03-24 |
| US10463686B2 (en) | 2019-11-05 |
| IL265370A (en) | 2019-05-30 |
| US20200138848A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292658A (en) | Immune modulation with tlr9 agonists for cancer treatment | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| CY1123993T1 (el) | Μεθοδος αγωγης καρκινου χρησιμοποιωντας αναστολεα σημειων ελεγχου ανοσιακου• αντισωμα που δεσμευεται σε υποδοχεα προγραμματισμενου θανατου-1 (pd-1) ή προσδετη 1 προγραμματισμενου θανατου (pd-l1) | |
| Wolchok et al. | Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma | |
| RU2017127966A (ru) | Применение плинабулина в комбинации с ингибиторами контрольной точки иммунного ответа | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| NZ724368A (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| JP2016528195A5 (https=) | ||
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| FI3303396T3 (fi) | Vasta-aineita ox40:ää vastaan ja niiden käyttöjä | |
| FI3218406T4 (fi) | Cd73:lle spesifisiä sitojamolekyylejä ja niiden käyttöjä | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| JP2018508572A5 (https=) | ||
| CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
| JP2017530950A5 (https=) | ||
| JP2018508512A5 (https=) | ||
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| RU2017120063A (ru) | Терапевтические комбинации для лечения неоплазии | |
| EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
| WO2019161221A3 (en) | Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| Vicier et al. | MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors |